摘要
目的分析孝感市中心医院下呼吸道感染患者常见病原菌及其耐药性,为临床治疗提供依据。方法采用双纸片协同试验(DDST)检测超广谱β-内酰胺酶(ESBLs),采用K-B法对病原菌进行药敏试验。结果分离出的466株病原菌中以肺炎克雷伯菌(148/466)、铜绿假单胞菌(110/466)、鲍曼不动杆菌(96/466)及大肠埃希菌(87/466)为主,金黄色葡萄球菌仅25例。肺炎克雷伯菌ESBLs试验阳性率为60.8%(90/148)。大肠埃希菌ESBLs试验阳性率为57.5%(50/87)。铜绿假单胞菌对哌拉西林(98.6%)、头孢唑啉(96.5%)、头孢呋辛(98.4%)、庆大霉素(96.8%)、复方新诺明(95.6%)的耐药率都非常高。鲍曼不动杆菌对哌拉西林、头孢唑啉、头孢呋辛和头孢他啶具有较高的耐药性,其耐药率分别为85.7%、88.4%、86.5%和85.4%。结论下呼吸道感染常见细菌的分布及耐药性有其特点,产ESBLs细菌耐药性不断增强,需监测和总结其规律性,为临床合理用药提供依据。
Objective To analyse the common pathogens and their drug resistance rates in patients with lower respiratory tract infection in Xiaogan Central Hospital in Hubei Province to provide the foundation for clinical treatment.Methods Adopt double paper joint test（DDST） to detect extended broad-spectrum beta-lactamase（ESBLs）,using Kirby-Bauer disk diffusion method for susceptibility testing of pathogens.Results 466strains of pathogenic bacteria isolated are Klebsiella pneumoniae（148 /466）,Pseudomonas aeruginosa（110 /466）,Acinetobacter baumannii（96 /466） and Escherichia coli（87 /466）.And there are only 25strains of Staphylococcus aureus isolated.The positive rate in ESBLs test of 148strains of Klebsiella pneumoniae was 60.8%（90 /148）.The positive rate in ESBLs test of Escherichia coli was 57.5%（50 /87）.Pseudomonas aeruginosa shows high drug resistance rates to piperacillin（98.6%）,cefazolin（96.5%）,cefuroxime（98.4%）,gentamycin（96.8%）,trimethoprim and sulphame-thoxazole（95.6%）.Acinetobacter baumannii shows high drug resistance rates to piperacillin,cefazolin,cefuroxime and cefotaxime,the resistance rates of which were 85.7%,88.4%,86.5%,85.4%,respectively.Conclusion The common bacteria distribution and drug resistance in lower respiratory tract infection exist characteristics.The drug resistance rates of ESBLs producing bacteria are growing,and need to be monitored to provide the basis for clinical treatment and rational drug use.
出处
《国际检验医学杂志》
CAS
2012年第11期1329-1330,1332,共3页
International Journal of Laboratory Medicine
关键词
下呼吸道感染
病原菌
超广谱Β-内酰胺酶
耐药性
lower respiratory tract infection； pathogens； extended broad-spectrum beta-lactamase； drug resistance；
